Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.

Pharmacogenomics - 1 Jun 2023

Zhang Zi Hao, Yue Sun Li Chao, Gu Hong Yan, Jiang De Chun, Yi Zhan Miao

Abstract excerpt

Objective: This meta-analysis was designed to investigate the associations between SLCO1B1, APOE and CYP2C9 and the lipid-lowering effects and pharmacokinetics of fluvastatin. Methods: Studies were searched from inception to March 2023, including three SNPs related to fluvastatin, SLCO1B1, CYP2C9 and APOE. Weighted mean differences and corresponding 95% CIs were analyzed to evaluate the associations between SNPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins E
Share to Cholesterol

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Liver-Specific Organic Anion Transporter 1

Source

Identifiers

PMID: 37318060
DOI: 10.2217/pgs-2023-0004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.PMID 37318060Read ↗

Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients.Semantic proximity Read ↗

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.Semantic proximity Read ↗

Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.Semantic proximity Read ↗

APOE genotype and the effect of statins: a systematic review and meta-analysisSemantic proximity Read ↗

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

APOE genotype and the effect of statins on lipid outcomes: A meta-analysis.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people.Semantic proximity Read ↗

Enantiospecific Pharmacogenomics of FluvastatinSemantic proximity Read ↗

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.Semantic proximity Read ↗

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.